Trial Profile

Efficacy and safety of pemafibrate in high risk patients with coronary artery disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemafibrate (Primary) ; Bezafibrate
Indications Hypertriglyceridaemia
Focus Therapeutic Use
Acronyms PEBE Trial; PEMA Trial

Most Recent Events

29 Aug 2022 Primary endpoint(percent change in the fasting serum triglyceride levels from baseline to the study endpoint after the 24-week treatment with bezafibrate or pemafibrate.) has been met according to the results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
29 Aug 2022 Results assessing Efficacy and safety of pemafibrate versus bezafibrate in coronary artery disease patients receiving statin treatment presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
17 May 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com